Scancell Holdings Plc (LON:SCLP)‘s stock had its “buy” rating reissued by equities research analysts at Panmure Gordon in a research note issued on Monday. They currently have a GBX 68 ($0.89) price target on the stock. Panmure Gordon’s price target indicates a potential upside of 325.00% from the stock’s current price.

Shares of Scancell Holdings Plc (LON:SCLP) opened at 16.60 on Monday. Scancell Holdings Plc has a one year low of GBX 12.00 and a one year high of GBX 25.90. The company has a 50-day moving average of GBX 16.92 and a 200 day moving average of GBX 17.17. The stock’s market cap is GBX 43.42 million.

About Scancell Holdings Plc

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.

Receive News & Ratings for Scancell Holdings Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell Holdings Plc and related companies with's FREE daily email newsletter.